Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue British Journal of Pharmacology Année : 2009

Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines

Résumé

Oxaliplatin is the first platinum-based compound effective in the treatment of colorectal cancer. Oxaliplatin combined with cetuximab for metastatic colorectal cancer is under evaluation. The preliminary results seem controversial, particularly for the use of cetuximab in K-Ras mutated patients. K-Ras mutation is known to affect redox homeostasis. Here we evaluated how the efficacy of oxaliplatin alone or combined with cetuximab varied according to the Ras mutation and redox status in a panel of colorectal tumour cell lines.

Dates et versions

hal-01744726 , version 1 (27-03-2018)

Identifiants

Citer

Laetitia Dahan, Amine Sadok, Jean-Louis Formento, Jean François Seitz, Hervé Kovacic. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. British Journal of Pharmacology, 2009, 158 (2), pp.610 - 620. ⟨10.1111/j.1476-5381.2009.00341.x⟩. ⟨hal-01744726⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More